The startup has developed a CRISPR-based platform for molecular diagnostics that enables multiplex detection of DNA and RNA biomarkers with the simplicity of Lateral Flow Assays and the precision of PCR. This technology enhances patient care by providing healthcare professionals with reliable diagnostic tools that facilitate informed healthcare decisions.
Funding
$550K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional molecular diagnostic methods like PCR often require specialized equipment, trained personnel, and laboratory infrastructure, limiting their accessibility at the point of care. This can lead to delays in diagnosis and treatment, particularly in resource-limited settings or situations requiring rapid results.
Solution
Leopard Biosciences is developing a CRISPR-based platform for molecular diagnostics that enables rapid, multiplexed detection of DNA and RNA biomarkers. The platform aims to combine the simplicity of lateral flow assays with the accuracy of PCR, making molecular diagnostics accessible at the point of care. By simplifying the testing process and eliminating the need for complex laboratory equipment, Leopard Biosciences intends to empower healthcare professionals and patients with reliable diagnostic tools for informed decision-making and improved patient outcomes. The technology is designed to be easy to use and deploy in a variety of settings, enabling faster diagnosis and treatment initiation.
Target Audience
The primary target audience includes healthcare professionals, such as doctors and nurses, particularly those working in point-of-care settings, as well as patients who require rapid and accessible diagnostic testing.
Features
- CRISPR-based technology for multiplex detection of DNA and RNA biomarkers
- Simplified workflow resembling lateral flow assays, minimizing user training requirements
- Accuracy and reliability comparable to PCR-based methods
- Potential for point-of-care deployment, eliminating the need for centralized laboratory infrastructure
- Rapid results, enabling timely clinical decision-making